Dyne therapeutics address
WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... WebARF Manager. Genocea Biosciences. Sep 2024 - Feb 20243 years 6 months. Cambridge, MA.
Dyne therapeutics address
Did you know?
WebMar 7, 2024 · Principal Scientist at Dyne Therapeutics . Brendan Quinn is a Principal Scientist at Dyne Therapeutics based in Waltham, Massachusetts. Previously, Brendan was an Associate Principal Scient ist at Harbour BioMed and also held positions at Otsuka America Pharmaceutical US, Johns Hopkins Medicine, National Institutes of Health, … WebAug 4, 2024 · - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2024 -. WALTHAM, Mass., Aug. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming …
WebDec 3, 2024 · Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy. WebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24.
WebMay 14, 2024 · However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release. Contact: Dyne Therapeutics Amy Reilly WebFind company research, competitor information, contact details & financial data for Dyne Therapeutics, Inc. of Waltham, MA. Get the latest business insights from Dun & …
WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to …
WebApr 3, 2024 · About Dyne Therapeutics Dyne Therapeutics is pioneering targeted therapies for patients with serious muscle diseases. Led by experts in therapeutic discovery and clinical development, Dyne is ... port industry dayWebMar 20, 2024 · positioned for growth. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people … port infection icd-10WebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10. port industry association nzWeb19 hours ago · Username or Email Address. Password. Keep Me Signed In What does "Remember ... Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne ... port inestownWebDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. port inesshireWebContact Transforming the gene therapy landscape with AI-powered AAV vectors. The Outlook Gene therapies of the future will be designed using artificial intelligence (AI) to reach more patients and treat many more diseases. Our Solution Dyno Therapeutics is applying AI technology to discover novel gene therapy vectors with transformative ... irnham lodge mineheadWebCompany profile page for Dyne Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information port infection bacteremia